NCT07494448 Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer Status NOT_YET_RECRUITING Phase PHASE1/PHASE2
NCT07413939 RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Status RECRUITING Phase PHASE2/PHASE3
NCT07318389 ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer Status NOT_YET_RECRUITING Phase EARLY_PHASE1
NCT06961331 Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer. Status COMPLETED Phase N/A
NCT06686394 Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) Status RECRUITING Phase PHASE1/PHASE2
NCT06439693 The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer Status RECRUITING Phase PHASE2
NCT06239467 First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer Status RECRUITING Phase PHASE1
NCT06162559 Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study Status RECRUITING Phase PHASE1
NCT06157892 A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors Status RECRUITING Phase PHASE2
NCT06067776 Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer Status NOT_YET_RECRUITING Phase PHASE1
NCT05892068 A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05748834 Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer Status RECRUITING Phase PHASE2
NCT05673928 A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB) Status RECRUITING Phase PHASE2
NCT05672524 A Study of Tucatinib and Trastuzumab in People With Rectal Cancer Status RECRUITING Phase PHASE2
NCT05583110 Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer Status TERMINATED Phase PHASE2
NCT05382364 Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002) Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT05356897 Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study Status WITHDRAWN Phase PHASE2
NCT05323955 Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib Status ACTIVE_NOT_RECRUITING Phase PHASE2